Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2509-4254
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer ; volume:6 ; number:6 ; day:15 ; month:9 ; year:2022 ; pages:899 ; date:11.2022
PharmacoEconomics - open ; 6, Heft 6 (15.9.2022), 899, 11.2022
- Creator
-
Elsea, David
Fan, Lin
Mihai, Adela
Moustaid, Fadoua El
Simmons, Daniel
Monberg, Matthew
Muston, Dominic
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s41669-022-00372-0
- URN
-
urn:nbn:de:101:1-2023011021070395277738
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Elsea, David
- Fan, Lin
- Mihai, Adela
- Moustaid, Fadoua El
- Simmons, Daniel
- Monberg, Matthew
- Muston, Dominic
- SpringerLink (Online service)
Other Objects (12)
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
Olaparib (Ovarialkarzinom; Erstlinie Erhaltung in Kombination mit Bevacizumab) : Addendum zum Auftrag A20-111
Olaparib (Ovarialkarzinom; Erstlinie Erhaltung in Kombination mit Bevacizumab) : Nutzenbewertung gemäß § 35a SGB V
Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Bevacizumab for patients with recurrent multifocal glioblastomas
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
Vitreous changes after intravitreal bevacizumab monotherapy for retinopathy of prematurity: a case series
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
Olaparib (Ovarialkarzinom; Erstlinie Erhaltung in Kombination mit Bevacizumab) : Addendum zum Auftrag A20-111
Olaparib (Ovarialkarzinom; Erstlinie Erhaltung in Kombination mit Bevacizumab) : Nutzenbewertung gemäß § 35a SGB V
Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Bevacizumab for patients with recurrent multifocal glioblastomas
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
Vitreous changes after intravitreal bevacizumab monotherapy for retinopathy of prematurity: a case series
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
Olaparib (Ovarialkarzinom; Erstlinie Erhaltung in Kombination mit Bevacizumab) : Addendum zum Auftrag A20-111
Olaparib (Ovarialkarzinom; Erstlinie Erhaltung in Kombination mit Bevacizumab) : Nutzenbewertung gemäß § 35a SGB V
Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Bevacizumab for patients with recurrent multifocal glioblastomas
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
Vitreous changes after intravitreal bevacizumab monotherapy for retinopathy of prematurity: a case series